Aera Therapeutics
Genetic medicine delivery company founded by Feng Zhang (Broad Institute) and ARCH Venture Partners, developing protein nanoparticle (PNP), targeted lipid nanoparticle (tLNP), and antibody-oligonucleotide conjugate platforms to unlock delivery beyond the liver.
Headquarters
Cambridge, USA
Year Founded
2023
Founders
Feng Zhang, Akin Akinc (CEO), John Maraganore (Board Chair)
Country
United States
Financial Information
Funding Stage
Series A & B
Recent Funding
$193M
Funding By
ARCH Venture Partners, GV, Series A/B investors
Core Technology
Protein nanoparticles (PNPs), tLNPs, AOCs
Product Type
Drug Delivery Platform
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: No
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Filed (Broad Institute foundational tech)
Partnerships
Pharma Collaborations
Multiple pharma collaborations
Academic / Hospital Tie-ups
Broad Institute of MIT and Harvard, University of Utah
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
Endogenous human protein capsids (PNPs) enabling extrahepatic delivery of genetic medicines